You are here

Article Text

Article menu
Download PDFPDF
PostScript
Letter
Ulcerative colitis as a sole mucosal disease: another misunderstanding?
  1. Joana Torres1,
  2. Vincent Billioud2,
  3. Laurent Peyrin-Biroulet2,
  4. Jean-Frédéric Colombel1
  1. 1The Henry D. Janowitz Division of Gastroenterology, Mount Sinai School of Medicine, New York, New York, USA
  2. 2Inserm, U954 and Department of Hepato-Gastroenterology, University Hospital of Nancy, Université Henri Poincaré 1, Vandoeuvre-lès-Nancy, France
  1. Correspondence to Professor Jean-Frédéric Colombel, The Henry D. Janowitz Division of Gastroenterology, Mount Sinai School of Medicine, 1 Gustave Levy Place, New York, NY 10029, USA; jean-frederic.colombel{at}wanadoo.fr

https://doi.org/10.1136/gutjnl-2011-300430

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    We read with great interest the paper by D'Haens and Ochsenkühn about the importance of mucosal healing (MH) in ulcerative colitis (UC).1 MH is considered to be a reliable indicator of treatment efficacy and a prognostic marker in UC. Since UC is classically described as a mucosal disease, as opposed to Crohn's disease (CD), MH seems the perfect therapeutic goal. In CD, it is accepted that treatment should go beyond symptomatic control and target the progressive course of the disease with reduction in bowel damage, prevention of complications and maintenance of gastrointestinal (GI) physiology. For UC, these goals have translated, for most investigators, in …

    View Full Text

    Footnotes

    • Competing interests None.

    • Provenance and peer review Not commissioned; internally peer reviewed.